Sep 21,2022

12-month real-world achievements for Diabeloop’s AID: – 4 million hours of hypoglycemia avoided – Trust in the algorithm leads to fewer meal declarations – Users report a significantly reduced mental load

Diabeloop, a leader in therapeutic AI applied to insulin delivery, reports today on 12 months of use of its hybrid closed-loop DBLG1 System on a large, multi-country patient cohort. While Time in Range (70-180 mg/dL) still shows constant improvement, time spent in hypoglycemia stays significantly low. Users share how these clinical results, combined with a growing trust in the algorithm has led to fewer interactions with the device and improved quality of life.

PRODUCT

#cgm

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Oct 05,2022

Continuous Glucose Monitoring (CGM) Market to Grow by 13% Annually Through 2027

The Continuous Glucose Monitoring (CGM) Market is expected to register a CAGR greater than 13% over the forecast period, 2022-2027. Governments around the world developed programs to educate diabetes patients and health care providers about the usage of continuous glucose monitoring devices. The German government provides training through Diabetes Care and Education Specialists under the names Flash, Spectrum, and other programs to train diabetes patients as well as other health care providers on how to use continuous glucose monitoring devices. A study in Korea conducted by the Korean Association of Diabetes Nurse Educators stated that the diabetes education program on how to use the Continuous Glucose Monitoring Devices increased the usage of devices.

#cgm

View Analyst & Ambassador Comments
Go to original news
Oct 06,2022

NEW STUDY PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE DEMONSTRATES ABBOTT'S FREESTYLE LIBRE® 2 SYSTEM HAS POSITIVE IMPACTS ON GLUCOSE LEVELS AND QUALITY OF LIFE

A new study published in The New England Journal of Medicine finds that for adults with Type 1 diabetes and sub-optimal glycemic control, Abbott's FreeStyle Libre® 2 glucose monitoring system provided significant reductions in glycated hemoglobin (HbA1c) compared to self-monitoring of blood glucose (SMBG), which were sustained for the study duration of 24 weeks.1 Use of the FreeStyle Libre 2 system was also linked to improvements in participant-reported quality of life outcomes, including overall satisfaction and reduction in burden associated with glucose monitoring.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Oct 07,2022

Analysts: Abbott, Dexcom to benefit from proposed CMS decision on CGMs

Analysts see a new proposed local coverage determination (LCD) from CMS as a potential boost for Dexcom (Nasdaq:DXCM) and Abbott (NYSE:ABT).

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Oct 09,2022 TOP STORY

Dexcom G7 launches in UK, Ireland, Germany, Austria and Hong Kong, kicking off global rollout of the world's most powerful continuous glucose monitoring system

DexCom, Inc. (Nasdaq: DXCM), the global leader in instant continuous glucose monitoring for people with diabetes, announced today that the Dexcom G7 Continuous Glucose Monitoring The (CGM) system is now available in the UK, Ireland, Germany, Austria and Hong Kong for people with diabetes aged two and over. This marks the first major milestone on the supply side of this revolutionary new technology. The company is also moving fast to bring the G7 to New Zealand and South Africa in the coming weeks, with plans to launch in other markets soon.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Oct 10,2022

ASCENSIA DIABETES CARE COMPLETES INITIAL EUROPEAN LAUNCH OF THE NEXT-GENERATION EVERSENSE E3 CONTUINOUS GLUCOSE MONITORING SYSTEM

Ascensia Diabetes Care, a global diabetes care company, maker of the CONTOUR® blood glucose monitoring (BGM) system portfolio and exclusive distributor of Eversense® Continuous Glucose Monitoring (CGM) Systems, announces that it has successfully completed the initial European launch of the next-generation Eversense® E3 CGM System. The unique benefits of this fully-implantable, long-term CGM system are now available to people with diabetes in all launch markets across Europe, as planned.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Oct 11,2022 TOP STORY

Ascensia completes Senseonics Eversense E3 European launch

Ascensia Diabetes Care announced that it successfully completed its initial European launch for the Senseonics (NYSE:SENS) Eversense E3. Eversense E3 represents Senseonics’ next-generation continuous glucose monitor (CGM) system. Eversense E3 can be used for up to six months (180 days). This doubles the wear time of its previous-generation CGM.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Oct 11,2022

GlucoTrack to begin R&D for new long-term CGM

GlucoTrack (Nasdaq:GCTK) announced that it plans to expand its product pipeline with an R&D program for a long-term continuous glucose monitor (CGM).

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Jan 08,2019

POCTech announced the establishment of global strategic collaboration relationship with Ascensia Diabetes Care

On January 8th 2019, Zhejiang POCTech Co., Led（POCTech） announced plans to cooperate with Ascensia Diabetes Care (ADC) on global multi-regional sales and to joint develop next generation of Continuous Glucose Monitoring (CGM) system. POCTech has reached agreements with Ascensia that appoint Ascensia to act as the sole distributor in 13 countries which POCTech has untapped. Meanwhile, Ascensia has the priority to be the exclusive agent of POCTech’s untapped markets. As a part of agreements, Ascensia will start to sell and promote POCTech’s CE certified CGM product (CT-100B) from mid-2019.

COLLABORATION PARTNERSHIP

#product & service

#cgm

View Analyst & Ambassador Comments
Go to original news
Jan 08,2019

Cecelia Health Partners with JCHR and the Helmsley Trust To Transform the Lives and Health Outcomes of People Living with Diabetes

Cecelia Health, a leading diabetes management technology- enabled personalized diabetes coaching company based in New York City, announced today it has partnered with The Jaeb Center for Health Research (JCHR) to pilot a study to remotely onboard and support people using Continuous Glucose Monitors (CGM). The study is funded by The Leona M. and Harry B. Helmsley Charitable Trust.

COLLABORATION PARTNERSHIP

#institution

#cgm

View Analyst & Ambassador Comments
Go to original news
Subscribe to CGM